

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

ANNOUNCEMENT IN RELATION TO THE RESIGNATION OF VICE CHAIRPERSON AND CHANGE OF AUTHORISED REPRESENTATIVE

On 6 March 2026, the board of directors (the “**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) received a written resignation from Ms. Cheng Ning (“**Ms. Cheng**”), resigning from her positions as the vice chairperson and an executive director of the 9th session of the Board, as a member of the Budget Committee of the Board and as an authorised representative (“**Authorised Representative**”) of the Company pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, due to her reaching the statutory retirement age. Upon her resignation, Ms. Cheng will no longer hold any position in the Company or its subsidiaries.

Ms. Cheng confirmed that she has no disagreement with the Board and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company.

In accordance with the relevant provisions of the Company Law and the Articles of Association of the Company, Ms. Cheng’s resignation will not cause the number of Board members to fall below the statutory minimum nor will it affect the normal operation of the Board. Her written resignation shall take effect upon delivery to the Board (that is, 6 March 2026). Ms. Cheng has no unfulfilled commitments or obligations, and has completed the handover procedures in accordance with the Company’s relevant regulations.

The Company and the Board wish to express their sincere gratitude to Ms. Cheng for her contributions to the development of the Company during her tenure.

Upon Ms. Cheng's resignation, she will cease to serve as an Authorised Representative of the Company. Ms. Huang Xuezhen, the Company Secretary of the Company, has been appointed as a new Authorised Representative of the Company with effect from 6 March 2026.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 6 March 2026

As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Chen Jiehui, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.